Suboxone Tooth Decay Lawsuit — MDL 3092: Eligibility, Evidence & What Plaintiffs Need to Know (2026)

Legal Disclaimer: This article is for general informational purposes only and is not legal advice. Individual case outcomes vary significantly. Consult a licensed attorney in your state for advice specific to your situation.

Suboxone’s Hidden Cost: How a Treatment Drug Became the Subject of 10,000+ Lawsuits

Suboxone was designed to save lives. For millions of Americans battling opioid use disorder, the combination of buprenorphine and naloxone dissolved under the tongue represented a medically supervised pathway to recovery. What the product’s labeling did not adequately communicate — for over a decade, according to plaintiffs — was the damage it was doing to their teeth.

MDL 3092 — In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation — is the federal mass tort that has collected these claims in the Northern District of Ohio before Judge Philip Calabrese. As of February 2026, the case count surpasses 10,000 claims when direct filings and bundled complaints are combined. The defendant: Indivior PLC and its US subsidiary, the manufacturer that brought Suboxone sublingual film to market around 2010.

The liability theory is focused: Indivior knew, or should have known, that dissolving an acidic film under the tongue repeatedly would erode tooth enamel — yet it failed to warn patients or dentists until the FDA compelled a label update in June 2022.

---

MDL 3092 Key Facts

Element	Detail
MDL Number	3092
Full Case Name	In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation
Court	US District Court, Northern District of Ohio
Judge	Hon. Philip Calabrese
Established	February 2024
Pending Claims	10,000+ (February 2026; ~1,853 individual filings + 9,000+ bundled)
Defendant	Indivior PLC / Indivior Inc.
Target Product	Suboxone sublingual film (buprenorphine/naloxone)
Bellwether Trial Target	Early 2028

---

The Science: Why a Sublingual Film Damages Teeth

Understanding the plaintiffs’ causation theory requires a brief chemistry lesson:

Mechanism 1: Acid Attack on Enamel

When a Suboxone film dissolves under the tongue, it creates an acidic microenvironment in the oral cavity. Tooth enamel begins to demineralize — lose its mineral structure — at pH levels below approximately 5.5. Repeated dissolution of the film bathes tooth surfaces in this acidic environment during each dose, multiple times daily.

Mechanism 2: Drug-Induced Xerostomia (Dry Mouth)

Buprenorphine, like other opioid-related compounds, reduces saliva production. Saliva performs critical oral protection functions: buffering pH, washing away food particles, and facilitating enamel remineralization. When saliva production is suppressed, the oral cavity loses its primary defense against acid erosion.

Combined Effect

Plaintiffs’ experts argue that the combination of repeated localized acidic pH exposure and chronically reduced salivary protection creates an accelerated enamel erosion pattern that is not adequately addressed by standard oral hygiene. The argument is not that this effect was unknowable — it is that Indivior failed to warn patients and clinicians before the FDA acted.

---

The FDA Warning Timeline: The Heart of the Liability Argument

The FDA warning history is itself a powerful piece of evidence:

Date	Event
~2010	Suboxone sublingual film enters US market
Ongoing	Post-market surveillance period; adverse event reports accumulate
January 12, 2022	FDA issues Drug Safety Communication warning of dental injuries with sublingual/buccal buprenorphine products; notes receiving “more than 300 reports” of tooth decay annually
June 2022	Suboxone prescribing label updated with formal dental warning

The gap — approximately 12 years between product launch and label warning — is what plaintiffs call the actionable failure. If Indivior’s own pharmacovigilance systems were receiving and processing adverse event data consistent with enamel erosion, the company had an obligation to act. The question for the jury will be: when did they actually know, and why did they wait?

---

Indivior’s Preemption Defense — The Key Legal Contest

In August 2024, Indivior filed a motion to dismiss arguing federal preemption. The company’s position: because the FDA controls drug labeling, Indivior could not have unilaterally added a dental warning without prior FDA approval, and therefore state-law failure-to-warn claims are preempted.

This argument has significant precedent working against it. In Wyeth v. Levine, 555 US 555 (2009), the Supreme Court held that brand-name drug manufacturers can update labels through the Changes Being Effected (CBE) regulation for newly identified risks — without waiting for FDA pre-approval. Preemption only applies if the FDA would have prohibited the change.

Plaintiffs’ counter-position: If Indivior had adverse event data suggesting dental harm, it could and should have added a dental warning years before the FDA acted in 2022. The failure to do so is exactly the kind of conduct the Wyeth exception is designed to address.

Judge Calabrese’s ruling on the dismissal motion is expected to significantly shape MDL 3092’s trajectory.

---

Three Hypothetical Case Profiles: What Makes a Claim Strong

Profile 1 — Strong Claim A 34-year-old woman used Suboxone film for 4 years to treat opioid use disorder. Before starting Suboxone, her dental records from annual checkups showed healthy teeth with no cavities. During Suboxone use, she developed 11 cavities, experienced rapid enamel erosion across multiple teeth, and ultimately required 5 extractions and dental implants. Her dentist documented “severe enamel erosion consistent with acid exposure, onset temporally correlated with Suboxone film use.”

Analysis: Pre-and-post dental record comparison is compelling. Objective documentation of injury, dentist’s causal observation, no competing risk factors. High-value claim.

Profile 2 — Contested Claim A 47-year-old man used Suboxone film for 2 years. He had a long history of dental neglect, multiple prior cavities, and still smokes. He developed additional tooth decay during Suboxone use.

Analysis: Multiple independent risk factors (smoking, prior decay, dental hygiene) complicate causation. Defense will argue existing dental disease was the cause, not the drug. The claim is not barred, but proving Suboxone’s contribution above and beyond baseline decay is the plaintiff’s burden.

Profile 3 — Catastrophic Long-Term User A 39-year-old man used Suboxone film for 6 years. Pre-treatment dental records show normal oral health. He lost 14 teeth during the treatment period and required full upper arch implant reconstruction at a cost of approximately $45,000. His prescribing physician never mentioned dental risks; the warnings were not on the label at the time.

Analysis: Long treatment duration, severe documented injury, high economic damages, absence of prior dental history, and proof that no warning was given. Strong candidate for high-damage bellwether selection.

---

How the MDL Bellwether Process Works

The logic of bellwether trials in pharmaceutical MDLs is straightforward: rather than resolving 10,000+ individual cases through separate trials, Judge Calabrese will select a representative set of cases to try before juries. The results:

1. Show both sides how juries evaluate the evidence
2. Generate dollar benchmarks that inform settlement negotiations
3. Identify which case categories are stronger or weaker

Judge Calabrese’s current roadmap:

• Census phase: Complete within 270 days — gathering case information from all plaintiffs
• Records pool: Select 500 cases for detailed records collection
• Trial candidates: Narrow to approximately 15 trial-ready cases
• Bellwether trials: Begin in early 2028

This is the industry-standard MDL architecture. If Indivior’s preemption defense fails (or is substantially limited), early bellwether verdicts favorable to plaintiffs would set the stage for a global settlement covering thousands of claims — potentially worth hundreds of millions of dollars, though no reliable estimate is possible at this stage.

See also: Mass Tort Settlement Payout Timeline | Class Action Settlement Guide

---

What Damages Can You Claim?

A successful Suboxone claim may allow recovery of:

Damage Category	Examples
Past dental expenses	Fillings, extractions, root canals, implants, dentures
Future dental costs	Ongoing maintenance of implants, additional procedures
Lost wages	Time off work for dental procedures
Pain and suffering	Chronic tooth pain, sensitivity, treatment discomfort
Emotional distress	Anxiety, depression, reduced self-esteem from tooth loss
Punitive damages	If willful concealment of dental risks is proven (varies by state)

---

Evidence Gathering Checklist for Suboxone Claims

Begin collecting these materials immediately:

• All Suboxone (or buprenorphine/naloxone film) prescriptions — prescribing physician, dates, doses
• Pharmacy fill records confirming actual dispensing throughout the treatment period
• Pre-treatment dental records — documenting baseline oral health before Suboxone
• Post-treatment dental records — documenting enamel erosion, cavities, tooth loss
• Dentist’s notes attributing or associating damage with medication use
• Invoices and receipts for all dental treatment related to the injuries
• Records of dental insurance claims and denials
• Documentation of ongoing dental care needs (future costs)
• Records of pain, functional limitation, or reduced quality of life
• Records of any communications with Indivior or prescribing physician about dental side effects

---

Finding the Right MDL Attorney

Not all personal injury attorneys handle pharmaceutical MDL litigation. The preemption defense alone — requiring familiarity with Wyeth v. Levine, FDA labeling regulations, and the CBE mechanism — demands specialized knowledge.

Evaluate any attorney for:

• Demonstrated MDL experience (prior pharmaceutical, medical device, or mass tort cases)
• Understanding of FDA drug labeling law and preemption doctrine
• Access to dental and oral medicine expert witnesses
• Knowledge of Suboxone pharmacology and the opioid treatment context
• Clear contingency fee agreement — typically 33–40% of recovery, zero upfront cost
• Track record of cases that reached favorable settlement or verdict

See also: Personal Injury Lawyer Fee Guide

---

Statute of Limitations — The Deadline That Cannot Be Extended

The most common reason valid plaintiffs lose their cases has nothing to do with the merits: they missed the filing deadline.

Product liability statutes of limitations vary by state. Most use some version of the “discovery rule” — the clock starts when you knew or should have known that Suboxone caused your dental injuries. For many plaintiffs, this clock may have started:

• When a dentist first noted unusual enamel erosion
• When the FDA published its January 2022 warning (for those who read it)
• When significant tooth loss first occurred

Some states have a hard outer limit (statute of repose) beyond which no claim is possible regardless of when you discovered the injury.

Do not assume you have time. Call an MDL attorney for a free consultation to determine your specific deadline.

See also: Hernia Mesh Lawsuit Guide | Paragard IUD Breakage Lawsuit | Medical Malpractice Lawsuit Guide

---

The Social Dimension: Tooth Loss in the Context of Opioid Recovery

The Suboxone MDL has a dimension that distinguishes it from many pharmaceutical mass torts: the plaintiffs were seeking treatment for addiction, one of the most socially stigmatized health conditions. The dental injuries they allegedly suffered as a result did not merely cause pain — they compounded the barriers to recovery and reintegration.

Tooth loss affects speech, eating, and appearance. For someone in early recovery, trying to secure employment or rebuild family relationships, severe dental damage creates an additional layer of hardship. This context matters in the damages calculation: pain and suffering awards in cases involving profound cosmetic injury and functional impairment tend to be higher than for invisible internal injuries of equivalent clinical severity.

Plaintiffs’ attorneys have argued this dimension effectively in preliminary briefings: patients who sought medical help were subjected to an undisclosed risk that impeded their ability to fully participate in society. The jury impact of this narrative — if bellwether cases go to trial — is a significant element of Indivior’s settlement calculus.

---

Generic Buprenorphine Film: A Different Legal Landscape

MDL 3092 focuses on Indivior’s branded Suboxone film. But many patients used generic buprenorphine/naloxone sublingual film, manufactured by companies like Amneal, Alvogen, or Teva. If you used generic film, your situation involves different legal considerations:

The Generic Pre-emption Problem

In PLIVA v. Mensing, 564 US 604 (2011), the Supreme Court held that generic drug manufacturers are required to use the same labeling as the brand-name reference drug and cannot independently update their labels. This means state-law failure-to-warn claims against generic manufacturers are generally federally preempted.

Practical Implication

If you exclusively used generic buprenorphine/naloxone film (not Indivior’s Suboxone), your claim against the generic manufacturer faces significant preemption obstacles that do not apply to the brand-name Suboxone claim against Indivior. However, if Indivior (as the brand-name reference drug holder) had the duty to update the label and failed to do so, some plaintiffs’ attorneys have argued that brand-name liability theory could extend even to patients who took the generic version — though this theory has had mixed success in various courts.

Consult an MDL specialist to evaluate your specific situation if you took generic film.

---

The Schedule A Settlement: What Indivior Has Already Disclosed

Indivior’s 10-K filings with the SEC reference a “Dental Allegations MDL Schedule A” arrangement, with dates including a Schedule A dated June 14, 2024, and subsequent events through February 7, 2025. The filing metadata suggests Indivior has been tracking and provisioning for dental litigation claims as a distinct category in its financial statements.

What this means for plaintiffs: Indivior is not treating the dental litigation as a nuisance case. The existence of a Schedule A designation in SEC filings — a mechanism typically used to organize settlement infrastructure — suggests the company is already working on a resolution framework. How large that framework is, and whether it will cover the full scope of claims, remains publicly undisclosed as of May 2026.

Verification note: The specific financial reserve amounts are contained in sections of Indivior’s 10-K that were not accessible through publicly available metadata. Refer to Indivior’s most recent 10-K filing (accessible at sec.gov) for current reserve disclosures.

---

The Patient Protection Angle: FDA’s January 2022 Warning in Context

The FDA’s January 12, 2022 Drug Safety Communication is worth examining in detail because it contains language that plaintiffs’ attorneys have highlighted in pleadings.

The FDA stated it had received reports of “dental problems including tooth decay, cavities, oral infections, and loss of teeth” and noted these events “can be serious.” The communication applied to all sublingual and buccal medications containing buprenorphine — a class-wide warning, not Suboxone-specific.

Critically, the FDA recommended healthcare providers counsel patients to: rinse their mouth with water after the film dissolves, avoid brushing teeth immediately after, and attend regular dental check-ups. This is preventive guidance that, plaintiffs argue, would have been actionable years earlier had Indivior disclosed the risk — and that could have prevented many of the injuries now forming the basis of litigation.

---

Recovery Options Beyond Litigation

If you have not yet pursued a legal claim, consider parallel avenues:

• Dental insurance claims: Document all Suboxone-related dental work through your insurance; this creates an important paper trail.
• Medicaid/Medicare coverage: If you qualified for public insurance during Suboxone treatment, dental costs may have been covered — those records are retrievable.
• Structured settlement planning: If your claim resolves, understanding payout options matters: Structured Settlement Guide

---

---

The Discovery Phase: What Internal Indivior Documents May Reveal

As in all pharmaceutical MDLs, the document discovery phase of MDL 3092 is where the most significant evidence is likely to emerge. Plaintiffs’ attorneys will seek:

Pharmacovigilance records: Indivior’s internal adverse event tracking for Suboxone film. The FDA’s own FAERS database logged over 300 annual dental injury reports before the 2022 warning — but internal pharmacovigilance data typically captures a broader, earlier dataset. If Indivior’s internal systems showed a dental signal years before January 2022, the CBE question becomes straightforward: they had the information and chose not to act.

Clinical trial and post-market study data: The sublingual film went through clinical trials and post-market studies. Whether gastric pH measurements, salivary flow studies, or enamel damage assessments were part of those protocols — and what the results showed — will be relevant to when the company should have known.

Internal communications on label decisions: Regulatory affairs teams at pharmaceutical companies maintain extensive files on label update decisions — what risk signals triggered review, what data was compiled, what the FDA was or was not consulted about. Communications that show awareness of dental risk being weighed against commercial interests in not adding a warning would be highly impactful with a jury.

Sales training and detailing materials: Suboxone’s sales representatives called on addiction medicine specialists and primary care physicians who treat opioid use disorder. Whether those representatives received training about dental side effects — and what they were told to say or not say — matters for the learned intermediary analysis.

The internal document production in MDL 3092 will likely be completed during 2025–2027, with the most sensitive materials contested through privilege logs and motion practice. The content of those documents, once produced, is what will most directly determine whether Indivior settles globally or fights bellwether trials.

---

Coordinating Your Dental and Legal Records: A Practical Timeline

One of the most common mistakes plaintiffs make is failing to maintain their dental care during the litigation process. This is counterproductive for two reasons:

1. Evidence preservation: Your current and ongoing dental condition is living evidence. Regular visits create a contemporaneous record of the state of your teeth and any continued deterioration. Gaps in dental care during litigation can allow the defense to argue that damage worsened due to neglect rather than the drug.

2. Quality of life and damages: Courts and settlement matrices recognize ongoing medical and dental costs as part of future damages. If you require additional implants, bridge work, or periodontal treatment in the coming years, those costs are potentially recoverable — but only if they are documented through actual dental treatment.

Recommended practice:

• Continue regular dental visits (minimum annual) during the litigation
• Ensure each visit captures a complete charting of current tooth status
• Keep all receipts for dental expenditures — these become part of your economic damages claim
• If a dentist notes a connection between your Suboxone history and current dental findings, ask them to document it explicitly in the chart

This may feel counterintuitive — why continue spending on dental care when you are suing over the costs? — but the ongoing documentation strengthens your claim and supports future damage projections.

---

MDL Terminology Every Suboxone Plaintiff Should Know

MDL (Multidistrict Litigation): A federal procedure that centralizes pretrial proceedings for related cases from different districts before a single judge. Not a class action — individual plaintiffs retain distinct cases and individual damages.

Bellwether Trial: A representative case selected to go to trial early to generate verdict data informing settlement negotiations for the broader MDL population.

Plaintiffs’ Steering Committee / Executive Committee: Court-appointed plaintiff attorneys who coordinate overall MDL strategy, manage common benefit discovery, and negotiate with Indivior on behalf of all plaintiffs.

Federal Preemption: The legal doctrine that federal law (here, FDA drug labeling requirements) supersedes state tort law claims. Brand-name drug preemption arguments face the Wyeth v. Levine counterprecedent; generic drug preemption arguments (from PLIVA v. Mensing) are considerably stronger for defendants.

CBE Regulation (Changes Being Effected): An FDA mechanism allowing brand-name drug manufacturers to strengthen safety labeling for newly identified risks without prior FDA approval, subject to concurrent notification and review. This is the central battleground in MDL 3092 — did Indivior have CBE-qualifying dental risk data that it chose not to act on?

Short Form Complaint: The abbreviated pleading an individual plaintiff files to join the MDL. It incorporates the Master Complaint by reference rather than restating all allegations individually.

Contingency Fee: Legal representation paid only upon recovery — typically 33–40% of the gross settlement or judgment before litigation costs.

---

Frequently Overlooked Damages in Suboxone Dental Claims

Plaintiffs focused on the immediate cost of dental treatment often undervalue their claims by missing less obvious damage categories:

Loss of Enjoyment of Life: Tooth loss and severe decay affect far more than chewing ability. The social and psychological impact — avoiding smiling, reluctance to speak in professional settings, withdrawal from social activities, anxiety about appearance — constitutes compensable “loss of enjoyment of life” in most jurisdictions. For patients in opioid recovery, where rebuilding social relationships and employment is critical, these losses can be profound.

Loss of Consortium: If your dental injuries affected your relationship with a spouse or domestic partner, a loss of consortium claim may be available in your state. These claims must typically be filed alongside the primary plaintiff’s claim.

Vocational Impact: For patients in customer-facing professions, healthcare, or any field where appearance matters, significant tooth loss can create demonstrable economic harm to earning capacity. An occupational expert can document this for the damages calculation.

Future Dental Costs — Lifetime Projection: Implants require maintenance and eventual replacement. Bone grafts may degrade. Periodontal complications may worsen. A dental economist or life care planner can project lifetime costs for patients who have undergone extensive reconstruction — projections that can reach $50,000–$100,000+ for severe multi-tooth loss cases.

Mental Health Treatment Costs: Patients who developed depression, anxiety, or social phobia as a result of dental disfigurement may have recoverable mental health treatment costs. Documenting any psychological treatment — therapy, psychiatric medication — strengthens this element of the claim.

Beginning to document all of these categories now, regardless of where the litigation stands, maximizes any eventual recovery.

---

Indivior Corporate Context: Who You Are Actually Suing

Understanding the corporate defendant provides context for the litigation’s dynamics and the realistic prospects for recovery:

Indivior PLC is a UK-headquartered specialty pharmaceutical company that spun off from Reckitt Benckiser in December 2014. Suboxone has historically represented a dominant portion of Indivior’s global revenue — making the litigation existentially significant to the company in a way that differs from a large pharmaceutical conglomerate like Johnson & Johnson or Pfizer, for whom one product represents a small fraction of total revenue.

Prior Opioid-Related Legal History: Indivior has prior experience with large-scale government enforcement. In 2019, Indivior PLC and its US subsidiary entered into criminal and civil resolutions with the US Department of Justice related to the marketing of Suboxone — specifically, allegations that Indivior improperly promoted the film over the tablet to protect market share. Indivior Inc. pleaded guilty to one count of making false statements related to healthcare matters and agreed to pay approximately $600 million. This prior conduct history — showing a pattern of prioritizing commercial interests over accurate disclosure — is the type of background evidence that plaintiff attorneys will argue supports punitive damages analysis in MDL 3092.

Financial Reserves: Indivior’s SEC filings reference a “Dental Allegations MDL Schedule A” structure, indicating the company has been provisioning financially for dental litigation claims. The specific reserve amounts are in the full text of Indivior’s 10-K filings, publicly available at sec.gov — the most recent filings covering fiscal years 2024 and 2025 would contain the most current figures.

This corporate context — a company with prior DOJ enforcement history, significant revenue concentration in Suboxone, and documented SEC financial provisioning for dental claims — provides the litigation with a factual backdrop that is quite different from cases against defendants with no prior conduct issues.

---

The Long View: What Resolution of MDL 3092 Could Look Like

No outcome is guaranteed, but historical patterns from comparable pharmaceutical MDLs suggest several possible trajectories for MDL 3092:

Scenario A — Global Settlement Before Bellwether If Indivior’s preemption defense is substantially rejected and discovery produces damaging internal documents, both sides may settle globally before any bellwether trial. This has occurred in some MDLs where the factual record became so adverse to the defendant that trials were deemed too risky. Settlement values in this scenario tend to be higher-range.

Scenario B — Post-Bellwether Settlement The more common pattern: one or more bellwether trials proceed, generating jury data. If plaintiff verdicts are returned, Indivior enters broader settlement negotiations. Settlement structure involves a points matrix, pro-rata distribution, and common benefit fee deductions. This process typically takes 2–4 years following the first bellwether verdict.

Scenario C — Continued Litigation If early bellwethers favor the defense — particularly if juries find for preemption or reject causation — the litigation may fragment. Some plaintiffs settle for modest amounts; others opt for individual state court trials. This is the least favorable scenario for the plaintiff class but remains possible if the causation science is effectively contested.

Most likely trajectory: Given the 10,000+ case count, the FDA’s own January 2022 safety communication (which validates the core allegation), and the absence of strong independent causation alternatives (dental decay is less ambiguous than a complex medical diagnosis), MDL 3092 is positioned for eventual global settlement — though the timeline and quantum depend heavily on Judge Calabrese’s ruling on preemption and the first bellwether results in 2028.

---

This article reflects publicly available litigation records and legal reporting as of May 2026. Case counts are based on data through February 2026 (About Lawsuits, court records); for current pending figures, refer to the JPML’s official statistics report at jpml.uscourts.gov. Nothing in this article constitutes legal advice or creates an attorney-client relationship.